Inspire Medical Systems (NYSE:INSP) Issues FY 2026 Earnings Guidance

Inspire Medical Systems (NYSE:INSP) issued an update on its FY 2026 earnings guidance on Monday morning. The company provided earnings per share guidance of 0.750-1.250 for the period, compared to the consensus earnings per share estimate of 1.990. The company issued revenue guidance of $825.0 million-$875.0 million, compared to the consensus revenue estimate of $961.2 million.

Inspire Medical Systems Trading Down 15.2%

INSP stock opened at $46.50 on Tuesday. The company has a market cap of $1.34 billion, a PE ratio of 9.14, a price-to-earnings-growth ratio of 2.92 and a beta of 0.83. The stock has a 50-day moving average price of $56.73 and a two-hundred day moving average price of $79.64. Inspire Medical Systems has a 12-month low of $48.30 and a 12-month high of $163.35.

Inspire Medical Systems (NYSE:INSP) last announced its earnings results on Monday, May 4th. The company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.28) by $0.38. Inspire Medical Systems had a return on equity of 10.96% and a net margin of 15.95%.The company had revenue of $204.58 million during the quarter, compared to the consensus estimate of $200.04 million. During the same period last year, the firm earned $0.10 earnings per share. The company’s revenue was up 1.6% on a year-over-year basis. Inspire Medical Systems has set its FY 2026 guidance at 0.750-1.250 EPS. Equities analysts forecast that Inspire Medical Systems will post 1.82 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities analysts have commented on INSP shares. Stifel Nicolaus decreased their target price on Inspire Medical Systems from $85.00 to $70.00 and set a “buy” rating for the company in a research note on Friday, April 10th. Mizuho dropped their price objective on shares of Inspire Medical Systems from $70.00 to $55.00 and set an “outperform” rating on the stock in a report on Tuesday. Royal Bank Of Canada reiterated a “sector perform” rating and issued a $56.00 price objective on shares of Inspire Medical Systems in a research report on Tuesday, April 14th. Bank of America reissued a “neutral” rating and set a $53.00 target price on shares of Inspire Medical Systems in a research note on Tuesday. Finally, Oppenheimer cut shares of Inspire Medical Systems from an “outperform” rating to a “market perform” rating in a research report on Thursday, January 22nd. Four investment analysts have rated the stock with a Buy rating, fifteen have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, Inspire Medical Systems has a consensus rating of “Hold” and an average price target of $94.89.

Inspire Medical Systems News Roundup

Here are the key news stories impacting Inspire Medical Systems this week:

• Positive Sentiment: Q1 results beat estimates — Inspire reported $0.10 EPS (vs. consensus loss) and $204.6M revenue, topping Street expectations and showing modest year-over-year sales growth. This supports the company’s underlying business strength. GlobeNewswire: Q1 Results
• Neutral Sentiment: Analyst note: Mizuho cut its price target from $70 to $55 but kept an “outperform” rating — the new target offers almost no upside versus the current price, so it is mixed (still favorable rating but lower conviction on upside). Benzinga
• Neutral Sentiment: Company materials and call transcript are available for investors reviewing management commentary and the details behind the guidance change. Earnings Call Summary (Yahoo)
• Negative Sentiment: Guidance cut — Inspire narrowed FY2026 EPS guidance to $0.75–$1.25 (street ~$1.99) and revenue to $825M–$875M (street ~$961M). Management cited reimbursement/coding issues and WISeR disruption as drivers of the downgrade, which materially reduces expected growth and margins. Seeking Alpha: Guidance & WISeR Disruption
• Negative Sentiment: Analyst downgrades/price-target cuts — Robert W. Baird cut its target to $50 and moved to “neutral”; Bank of America reaffirmed “neutral” with a $53 target. Those moves signal reduced analyst confidence and put further pressure on the shares. The Fly: Baird Note
• Negative Sentiment: Market reaction: coverage and headlines emphasizing the guidance cut and reimbursement uncertainty drove a sharp intraday sell-off (coverage noted a large single-day decline following the update). Yahoo Finance: Stock Reaction

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the business. Smartleaf Asset Management LLC lifted its position in shares of Inspire Medical Systems by 84.0% during the 4th quarter. Smartleaf Asset Management LLC now owns 449 shares of the company’s stock valued at $42,000 after acquiring an additional 205 shares during the last quarter. Larson Financial Group LLC grew its holdings in shares of Inspire Medical Systems by 21,266.7% in the 3rd quarter. Larson Financial Group LLC now owns 641 shares of the company’s stock worth $48,000 after acquiring an additional 638 shares during the last quarter. Quarry LP grew its holdings in shares of Inspire Medical Systems by 695.1% in the 4th quarter. Quarry LP now owns 644 shares of the company’s stock worth $59,000 after acquiring an additional 563 shares during the last quarter. Daiwa Securities Group Inc. grew its holdings in shares of Inspire Medical Systems by 38.7% in the 2nd quarter. Daiwa Securities Group Inc. now owns 466 shares of the company’s stock worth $60,000 after acquiring an additional 130 shares during the last quarter. Finally, Parallel Advisors LLC raised its position in shares of Inspire Medical Systems by 349.7% during the fourth quarter. Parallel Advisors LLC now owns 715 shares of the company’s stock worth $66,000 after purchasing an additional 556 shares during the period. Institutional investors and hedge funds own 94.91% of the company’s stock.

About Inspire Medical Systems

Inspire Medical Systems, Inc is a medical technology company specializing in implantable neurostimulation devices for the treatment of obstructive sleep apnea (OSA). The company’s flagship offering, the Inspire® system, delivers targeted stimulation of the hypoglossal nerve to maintain airway patency during sleep, providing an alternative therapy for patients who are intolerant of or inadequately managed by continuous positive airway pressure (CPAP) devices.

The Inspire system comprises an implantable pulse generator, a sensing lead that monitors breathing patterns, and a stimulation lead that activates the hypoglossal nerve.